Citations (131)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Dody Priambada, Muhamad Thohar Arifin, Abdi Saputro, Azka Muzakka, Vega Karlowee, Udadi Sadhana, Yuriz Bakhtiar, Krisna Tsaniadi Prihastomo, Ajid Risdianto, Happy Kurnia Brotoarianto, Erie Andar & Zainal Muttaqin. (2023) Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients. International Journal of General Medicine 16, pages 393-403.
Read now
Read now
Yong Ling, Zhi-You Hao, Dong Liang, Chun-Lei Zhang, Yan-Fei Liu & Yan Wang. (2021) The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Design, Development and Therapy 15, pages 4289-4338.
Read now
Read now
Mara Persano, Marco Puzzoni, Pina Ziranu, Valeria Pusceddu, Eleonora Lai, Andrea Pretta, Clelia Donisi, Giovanna Pinna, Dario Spanu, Erika Cimbro, Alissa Parrino, Nicole Liscia, Stefano Mariani, Marco Dubois, Marco Migliari & Mario Scartozzi. (2021) Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Review of Anticancer Therapy 21:11, pages 1253-1264.
Read now
Read now
Angelos Angelakas, Angela Lamarca, Richard a Hubner, Mairéad G McNamara & Juan W. Valle. (2021) Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Expert Opinion on Investigational Drugs 30:4, pages 301-307.
Read now
Read now
Qurat Ul Ain Riaz Sipra & Rachna Shroff. (2021) The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs 30:4, pages 281-284.
Read now
Read now
Laura E. Russell, Yitian Zhou, Ahmed A. Almousa, Jasleen K. Sodhi, Chukwunonso K. Nwabufo & Volker M. Lauschke. (2021) Pharmacogenomics in the era of next generation sequencing – from byte to bedside. Drug Metabolism Reviews 53:2, pages 253-278.
Read now
Read now
Liliana Rodrigues, Pedro Cravo & Miguel Viveiros. (2020) Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. Expert Review of Anti-infective Therapy 18:8, pages 741-757.
Read now
Read now
Jin Zhu, Ya-Peng Zhao & Yu-Qi Zhang. (2020) Low expression of FOSL1 is associated with favorable prognosis and sensitivity to radiation/pharmaceutical therapy in lower grade glioma. Neurological Research 42:6, pages 522-527.
Read now
Read now
Christian Gerecke, Fabian Schumacher, Alide Berndzen, Thomas Homann & Burkhard Kleuser. (2020) Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells. Epigenetics 15:3, pages 307-322.
Read now
Read now
Articles from other publishers (122)
Samprikta Manna, Julia Scheel, Aisling Noone, Colm J. McElwain, Caitriona Scaife, Shailendra Gupta, Jane English, Cathal McCarthy & Fergus P. McCarthy. (2023) A proteomic profile of the healthy human placenta. Clinical Proteomics 20:1.
Crossref
Crossref
Shuang Liu, Martine Abboud, Victor Mikhailov, Xiao Liu, Raphael Reinbold & Christopher J. Schofield. (2023) Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. Journal of Medicinal Chemistry 66:7, pages 5279-5288.
Crossref
Crossref
Yang Liu, Wei Xu, Mingxue Li, Yueying Yang, Dejuan Sun, Lidian Chen, Hua Li & Lixia Chen. (2023) The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Acta Pharmaceutica Sinica B 13:4, pages 1438-1466.
Crossref
Crossref
Tariq D. Al-Saadi & Roberto J. Diaz. 2023. Glioblastoma - Current Evidence. Glioblastoma - Current Evidence.
Matthew Willman, Jonathan Willman, John Figg, Emma Dioso, Sai Sriram, Bankole Olowofela, Kevin Chacko, Jairo Hernandez & Brandon Lucke-Wold. (2023) Update for astrocytomas: medical and surgical management considerations. Exploration of Neuroscience, pages 1-26.
Crossref
Crossref
Jinjin Zhang, Xiaopeng Wang, Congkuan Song & Qi Li. (2023) Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways. BMC Cancer 23:1.
Crossref
Crossref
Juan Jose Rodriguez-Sevilla, Vera Adema, Guillermo Garcia-Manero & Simona Colla. (2023) Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Reports Medicine 4:2, pages 100940.
Crossref
Crossref
Yu-Wen Cheng, Yang-Yi Chen, Chien-Ju Lin, Yi-Ting Chen, Ann-Shung Lieu, Hung-Pei Tsai & Aij-Lie Kwan. (2022) High expression of NLRP12 predicts poor prognosis in patients with intracranial glioma. Journal of the Chinese Medical Association 86:1, pages 88-97.
Crossref
Crossref
Amr Elagamy, Laila K. Elghoneimy & Reem K. Arafa. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
375
410
.
Kun-Hao Bai, Ming-Jiao Zhu, Yi-Yang Zhang, Xue-Ping Li, Si-Liang Chen, Da-Wei Wang & Yu-Jun Dai. (2022) Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM). Frontiers in Immunology 13.
Crossref
Crossref
Xiaofeng Yin, Quansheng Wu, Zheng Hao & Laizhao Chen. (2022) Identification of novel prognostic targets in glioblastoma using bioinformatics analysis. BioMedical Engineering OnLine 21:1.
Crossref
Crossref
Joseph Ho, Constance Fiocco & Kristen Spencer. (2022) Treating Biliary Tract Cancers: New Targets and Therapies. Drugs 82:17, pages 1629-1647.
Crossref
Crossref
Alexander Yuile, Laveniya Satgunaseelan, Joe Wei, Marina Kastelan, Michael F. Back, Maggie Lee, Heng Wei, Michael E. Buckland, Adrian Lee & Helen R. Wheeler. (2022) Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review. Current Issues in Molecular Biology 44:10, pages 5117-5125.
Crossref
Crossref
Yuqi Zhang, Abdullah Esmail, Vincenzo Mazzaferro & Maen Abdelrahim. (2022) Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers 14:20, pages 5074.
Crossref
Crossref
Zhirui Zeng, Chujiao Hu, Wanyuan Ruan, Jinjuan Zhang, Shan Lei, Yushi Yang, Pailan Peng, Feng Pan & Tengxiang Chen. (2022) A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy. Frontiers in Immunology 13.
Crossref
Crossref
Chujiao Hu, Zhirui Zeng, Dan Ma, Zhixin Yin, Shanshan Zhao, Tengxiang Chen, Lei Tang & Shi Zuo. (2022) Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. Frontiers in Pharmacology 13.
Crossref
Crossref
Zijian Liu, Jinlan He & Xiaolin Hu. (2022) Ferroptosis regulators related scoring system by Gaussian finite mixture model to predict prognosis and immunotherapy efficacy in nasopharyngeal carcinoma. Frontiers in Genetics 13.
Crossref
Crossref
Zachary J. Brown, Satyajit Patwardhan, Joal Bean & Timothy M. Pawlik. (2022) Molecular diagnostics and biomarkers in cholangiocarcinoma. Surgical Oncology 44, pages 101851.
Crossref
Crossref
Xin Zhao, Huan-qiu Liu, Li-na Wang, Le Yang & Xiao-liang Liu. (2022) Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Seminars in Cancer Biology 83, pages 121-135.
Crossref
Crossref
Baolin Zhou, Fang Yang, Lei Qin, Jun Kuai, Lu Yang, Lanfang Zhang, Peisheng Sun, Guangpeng Li & Xinhui Wang. (2022) Computational study on novel natural compound inhibitor targeting IDH1_R132H. Aging 14:13, pages 5478-5492.
Crossref
Crossref
Claudia Peitzsch, Ielizaveta Gorodetska, Daria Klusa, Qihui Shi, Tiago C. Alves, Klaus Pantel & Anna Dubrovska. (2022) Metabolic regulation of prostate cancer heterogeneity and plasticity. Seminars in Cancer Biology 82, pages 94-119.
Crossref
Crossref
Fabiana Cacace, Rossella Iula, Danilo De Novellis, Valeria Caprioli, Maria Rosaria D’Amico, Giuseppina De Simone, Rosanna Cuccurullo, William G. Wierda, Kris Michael Mahadeo, Giuseppe Menna & Francesco Paolo Tambaro. (2022) High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines 10:6, pages 1405.
Crossref
Crossref
Yiming Gong, Hao-Yuan Zhang, Ying Yuan, Yongmeng He, Weiyi Zhang, Yanguo Han, Risu Na, Yan Zeng, Jia Luo, Haili Yang, Yongfu Huang, Yongju Zhao, Zhongquan Zhao & Guang-Xin E. (2022) Genome-Wide Selection Sweep between Wild and Local Pigs from Europe for the Investigation of the Hereditary Characteristics of Domestication in Sus Scrofa. Animals 12:8, pages 1037.
Crossref
Crossref
Simon Gray, Angela Lamarca, Julien Edeline, Heinz-Josef Klümpen, Richard A. Hubner, Mairéad G. McNamara & Juan W. Valle. (2022) Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 14:7, pages 1789.
Crossref
Crossref
Robert P. Ostrowski & Emanuela B. Pucko. (2022) Harnessing oxidative stress for anti-glioma therapy. Neurochemistry International 154, pages 105281.
Crossref
Crossref
Erica Brivio, André Baruchel, Auke Beishuizen, Jean-Pierre Bourquin, Patrick A. Brown, Todd Cooper, Lia Gore, E. Anders Kolb, Franco Locatelli, Shannon L. Maude, Francis J. Mussai, Britta Vormoor-Bürger, Josef Vormoor, Arend von Stackelberg & C. Michel Zwaan. (2022) Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. European Journal of Cancer 164, pages 1-17.
Crossref
Crossref
Monika Lejman, Izabela Dziatkiewicz & Mateusz Jurek. (2022) Straight to the Point—The Novel Strategies to Cure Pediatric AML. International Journal of Molecular Sciences 23:4, pages 1968.
Crossref
Crossref
Pedro Valente Aguiar, Osvaldo Sousa, Roberto Silva, Rui Vaz & Paulo Linhares. (2022) Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping. Neurocirugía 33:1, pages 31-34.
Crossref
Crossref
Pedro Valente Aguiar, Osvaldo Sousa, Roberto Silva, Rui Vaz & Paulo Linhares. (2022) Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping. Neurocirugía (English Edition) 33:1, pages 31-34.
Crossref
Crossref
Michèle Brivet, Pauline Gaignard & Manuel Schiff. 2022. Inborn Metabolic Diseases. Inborn Metabolic Diseases
269
286
.
Heba Alkhatabi, Haneen Abdulfattah Bin Saddeq, Luay Alyamani, Thoraia Shinawi, Elrashed B. Yasin, Raed Alserihi, Raed Felimban, Hossam H. Tayeb, Rawan Mimani, Zainab Alalla, Muhammad Abu-Elmagd & Adel Abuzenadah. (2021) Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia. Genes 12:12, pages 1963.
Crossref
Crossref
Manendra Singh Tomar, Ashok Kumar, Chhitij Srivastava & Ashutosh Shrivastava. (2021) Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188616.
Crossref
Crossref
Jia-Huei Tsai, Jau-Yu Liau, Chia-Hsiang Lee & Yung-Ming Jeng. (2021) Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection. American Journal of Surgical Pathology 45:10, pages 1409-1418.
Crossref
Crossref
Hanjun Cheng, Zhonghan Li, Zhili Guo, Shiqun Shao, Li Mo, Wei Wei & Min Xue. (2021) Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs. Biosensors and Bioelectronics 190, pages 113368.
Crossref
Crossref
Fu-Ju Chou, Yang Liu, Fengchao Lang & Chunzhang Yang. (2021) D-2-Hydroxyglutarate in Glioma Biology. Cells 10:9, pages 2345.
Crossref
Crossref
J. Jian, Y. Qiao, Y. Li, Y. Guo, H. Ma & B. Liu. (2021) Mutations in chronic myelomonocytic leukemia and their prognostic relevance. Clinical and Translational Oncology 23:9, pages 1731-1742.
Crossref
Crossref
Tal Gutman, Guy Goren, Omri Efroni & Tamir Tuller. (2021) Estimating the predictive power of silent mutations on cancer classification and prognosis. npj Genomic Medicine 6:1.
Crossref
Crossref
Paula M. Wagner, César G. Prucca, Beatriz L. Caputto & Mario E. Guido. (2021) Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. International Journal of Molecular Sciences 22:15, pages 8289.
Crossref
Crossref
Dong Shen, Junling Zhang, Kai Yuan, Jing Zhao, Zhengyi Zhao, Longgang Cui, Yuzi Zhang, Guoqiang Wang, Shangli Cai, Yuezong Bai, Wei Li & Xiang Huang. (2021)
Landscape of
IDH1/2
mutations in Chinese patients with solid tumors: A pan‐cancer analysis
. Molecular Genetics & Genomic Medicine 9:8.
Crossref
Crossref
Pei Zhang, Xinyi Meng, Liqun Liu, Shengzhen Li, Yang Li, Sakhawat Ali, Shanhu Li, Jichuan Xiong, Xuefeng Liu, Shouwei Li, Qin Xia & Lei Dong. (2021) Identification of the Prognostic Signatures of Glioma With Different PTEN Status. Frontiers in Oncology 11.
Crossref
Crossref
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi & Alba Ariela Brandes. (2021) IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. Molecular Diagnosis & Therapy 25:4, pages 457-473.
Crossref
Crossref
Natalia Di Ianni, Silvia Musio & Serena Pellegatta. (2021) Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction. International Journal of Molecular Sciences 22:9, pages 4460.
Crossref
Crossref
Qun Li, Xiaoyan Zhang, Jiao Feng, Dezhi Cheng, Lin Cai, Zhang’an Dai, Shuyu Zhao, Jianmin Li, Jingjing Huang, Yu Fang, Honglin Zhu, Danhua Wang, Sizhen Wang, Tonghui Ma & Xianghe Lu. (2021) Case Report: Next-Generation Sequencing Reveals Tumor Origin in a Female Patient With Brain Metastases. Frontiers in Oncology 11.
Crossref
Crossref
Kunwar Singh, Sumanth Gollapudi, Sasha Mittal, Corinn Small, Jyoti Kumar & Robert Ohgami. (2021) Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Diagnostics 11:4, pages 600.
Crossref
Crossref
Zhengwei Wu, Yi Fei Lee, Xun Hui Yeo, Ser Yue Loo & Wai Leong Tam. (2021) Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer. Cancers 13:6, pages 1316.
Crossref
Crossref
Nai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, Chun-Nan Yeh & Ming-Huang Chen. (2021) Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 11:1, pages 97.
Crossref
Crossref
明婷 杨. (2021) Advances in the Treatment of Adult Relapsed/Refractory Acute Myeloid Leukemia. Advances in Clinical Medicine 11:01, pages 24-33.
Crossref
Crossref
Linchen Li, Min Zhang, Dengna Zhu & Xinjun Wang. (2021) High expression of cluster of differentiation 276 indicates poor prognosis in glioma. Clinical Medicine Insights: Oncology 15, pages 117955492110323.
Crossref
Crossref
Maria J. Merino, Christopher J. Ricketts, Vanessa Moreno, Ye Yang, Teresa W.M. Fan, Andrew N. Lane, Paul S. Meltzer, Cathy D. Vocke, Daniel R. Crooks & William M. Linehan. (2021) Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm. American Journal of Surgical Pathology 45:1, pages 137-142.
Crossref
Crossref
Roberta Rudà, Mehdi Touat & Riccardo Soffietti. (2020) Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. Current Opinion in Neurology 33:6, pages 707-715.
Crossref
Crossref
Joséphine Briand, Aurélien A. Sérandour, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Dominique Heymann, Benjamin Ory, François M. Vallette & Pierre-François Cartron. (2020) N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool. Molecular Therapy - Nucleic Acids 22, pages 72-83.
Crossref
Crossref
Baptiste Louveau, Fanélie Jouenne, Pauline Têtu, Aurélie Sadoux, Aurélia Gruber, Eddie Lopes, Julie Delyon, Kevin Serror, Oren Marco, Laetitia Da Meda, Aminata Ndiaye, Alban Lermine, Nicolas Dumaz, Maxime Battistella, Barouyr Baroudjian, Céleste Lebbe & Samia Mourah. (2020) A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Targeted Oncology 15:6, pages 759-771.
Crossref
Crossref
Nicola Personeni, Ana Lleo, Tiziana Pressiani, Francesca Colapietro, Mark Robert Openshaw, Chara Stavraka, Athanasios Pouptsis, David James Pinato & Lorenza Rimassa. (2020) Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers 12:11, pages 3370.
Crossref
Crossref
Sally C. Fletcher & Mathew L. Coleman. (2020) Human 2-oxoglutarate-dependent oxygenases: nutrient sensors, stress responders, and disease mediators. Biochemical Society Transactions 48:5, pages 1843-1858.
Crossref
Crossref
Manjusha Vaidya & Kiminobu Sugaya. (2020) DNA Associated with Circulating Exosomes as a Biomarker for Glioma. Genes 11:11, pages 1276.
Crossref
Crossref
Hyeon Ji Kim & Do-Yeon Kim. (2020) Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules 25:20, pages 4641.
Crossref
Crossref
Yu-Chan Chang, Ming-Huang Chen, Chun-Nan Yeh & Michael Hsiao. (2020) Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 10:10, pages 1377.
Crossref
Crossref
Pei Zhang, Qin Xia, Liqun Liu, Shouwei Li & Lei Dong. (2020) Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito & Matteo Landriscina. (2020) IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives. Molecules 25:16, pages 3754.
Crossref
Crossref
Laetitia Federici, Laurent Capelle, Maxime Annereau, Franck Bielle, Christophe Willekens, Caroline Dehais, Florence Laigle-Donadey, Khê Hoang-Xuan, Jean-Yves Delattre, Ahmed Idbaih, Francois Lemare, Stéphane de Botton, Marc Sanson & Mehdi Touat. (2020) 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma. Neuro-Oncology 22:8, pages 1226-1228.
Crossref
Crossref
Irene Vanni, Enrica Teresa Tanda, Bruna Dalmasso, Lorenza Pastorino, Virginia Andreotti, William Bruno, Andrea Boutros, Francesco Spagnolo & Paola Ghiorzo. (2020) Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Maria Andrea Desbats, Isabella Giacomini, Tommaso Prayer-Galetti & Monica Montopoli. (2020) Metabolic Plasticity in Chemotherapy Resistance. Frontiers in Oncology 10.
Crossref
Crossref
Lennard J. M. Dekker, Suying Wu, Cherise Jurriëns, Dana A. N. Mustafa, Frederieke Grevers, Peter C. Burgers, Peter A. E. Sillevis Smitt, Johan M. Kros & Theo M. Luider. (2020) Metabolic changes related to the IDH1 mutation in gliomas preserve TCA‐cycle activity: An investigation at the protein level. The FASEB Journal 34:3, pages 3646-3657.
Crossref
Crossref
Behrouz Hassannia, Emilie Logie, Peter Vandenabeele, Tom Vanden Berghe & Wim Vanden Berghe. (2020) Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug. Biochemical Pharmacology 173, pages 113602.
Crossref
Crossref
Albert Roessner, Maria Smolle, Victor Schoeder & Johannes Haybaeck. (2020) Knorpeltumoren: Morphologie, Genetik und Basisaspekte der TargettherapieCartilage tumors: morphology, genetics, and current aspects of target therapy. Der Pathologe 41:2, pages 143-152.
Crossref
Crossref
Longzhen Cui, Yan Liu, Yifan Pang, Tingting Qian, Liang Quan, Zhiheng Cheng, Yifeng Dai, Xu Ye, Ying Pang, Jinlong Shi, Xiaoyan Ke, Depei Wu & Lin Fu. (2019) Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Therapy 27:1-2, pages 1-14.
Crossref
Crossref
Murtala B. Abubakar & Siew Hua Gan. 2020. An Evidence-Based Approach to the Management of Nasopharyngeal Cancer. An Evidence-Based Approach to the Management of Nasopharyngeal Cancer
31
66
.
Jubert Marquez, Jessa Flores, Amy Hyein Kim, Bayalagmaa Nyamaa, Anh Thi Tuyet Nguyen, Nammi Park & Jin Han. (2019) Rescue of TCA Cycle Dysfunction for Cancer Therapy. Journal of Clinical Medicine 8:12, pages 2161.
Crossref
Crossref
Krissie Lenting, Corina N. A. M. van den Heuvel, Anne van Ewijk, Duaa ElMelik, Remco de Boer, Elizabeth Tindall, Ge Wei, Benno Kusters, Maarten te Dorsthorst, Mark ter Laan, Martijn A. Huynen & William P. Leenders. (2019) Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing. Acta Neuropathologica Communications 7:1.
Crossref
Crossref
Rakel Brendsdal Forthun, Randi Hovland, Cornelia Schuster, Hanne Puntervoll, Hans Petter Brodal, Heidi Maria Namløs, Lars Birger Aasheim, Leonardo A. Meza-Zepeda, Bjørn Tore Gjertsen, Stian Knappskog & Oddbjørn Straume. (2019) ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports 9:1.
Crossref
Crossref
Essia Saiji, Fabienne Gumy Pause, Pierre Lascombes, Christelle Cerato Biderbost, Nathalie Lin Marq, Margaret Berczy, Laura Merlini & Anne-Laure Rougemont. (2019) IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis. Virchows Archiv 475:5, pages 625-636.
Crossref
Crossref
Jin Zhu & Yu-Qi Zhang. (2019) Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma. PeerJ 7, pages e7414.
Crossref
Crossref
Kenichi Miyamoto & Yosuke Minami. (2019) Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. International Journal of Clinical Oncology 24:8, pages 893-898.
Crossref
Crossref
Cristina Papayannidis, Chiara Sartor, Giovanni Marconi, Maria Chiara Fontana, Jacopo Nanni, Gianluca Cristiano, Sarah Parisi, Stefania Paolini & Antonio Curti. (2019) Acute Myeloid Leukemia Mutations: Therapeutic Implications. International Journal of Molecular Sciences 20:11, pages 2721.
Crossref
Crossref
Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S. Modrek & Dimitris G. Placantonakis. (2019) Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Frontiers in Oncology 9.
Crossref
Crossref
Serena Tommasini-Ghelfi, Kevin Murnan, Fotini M. KouriAkanksha S. MahajanJasmine L. May & Alexander H. Stegh. (2019) Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Science Advances 5:5.
Crossref
Crossref
Xing Zhang, Runchen Miao, Tian Liu, Xiaohong Xiang, Jingxian Gu, Yifan Jia, Zeyu Li, Yunong Fu, Yang He, Yuhua Zhang, Jingyao Zhang, Kai Qu & Chang Liu. (2019) IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma. Biomedicine & Pharmacotherapy 113, pages 108774.
Crossref
Crossref
Emma H. McCafferty & Katherine A. Lyseng-Williamson. (2019) Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA. Drugs & Therapy Perspectives 35:4, pages 160-166.
Crossref
Crossref
Suneel Deepak Kamath, Xiaoqi Lin & Aparna Kalyan. (2019)
A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an
IDH1
Mutation
. The Oncologist 24:2, pages 151-156.
Crossref
Crossref
Jinpeng Liu, Thilakam Murali, Tianxin Yu, Chunming Liu, Theru A. Sivakumaran, Hunter N.B. Moseley, Igor B. Zhulin, Heidi L. Weiss, Eric B. Durbin, Sally R. Ellingson, Jinze Liu, Bin Huang, Brent J. Hallahan, Craig M. Horbinski, Kurt Hodges, Dana L. Napier, Thèrése Bocklage, Joseph Mueller, Nathan L. Vanderford, David W. Fardo, Chi Wang & Susanne M. Arnold. (2019) Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky. Cancer Epidemiology, Biomarkers & Prevention 28:2, pages 348-356.
Crossref
Crossref
Matthias Tallegas, Élodie Miquelestorena-Standley, Corinne Labit-Bouvier, Cécile Badoual, Arnaud Francois, Anne Gomez-Brouchet, Sébastien Aubert, Christine Collin, Anne Tallet & Gonzague de Pinieux. (2019) IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract. Human Pathology 84, pages 183-191.
Crossref
Crossref
Shayan Cheraghlou, Young Lim & Keith Choate. (2019) Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention. F1000Research 8, pages 590.
Crossref
Crossref
Francesca Ricci, Laura Brunelli, Roberta Affatato, Rosaria Chilà, Martina Verza, Stefano Indraccolo, Francesca Falcetta, Maddalena Fratelli, Robert Fruscio, Roberta Pastorelli & Giovanna Damia. (2019) Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. Therapeutic Advances in Medical Oncology 11, pages 175883591983954.
Crossref
Crossref
Feixiong Cheng, Han Liang, Atul J. Butte, Charis Eng & Ruth Nussinov. (2019) Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. Pharmacological Reviews 71:1, pages 1-19.
Crossref
Crossref
Shigeo Ohba & Yuichi Hirose. (2018) Association between mutant IDHs and tumorigenesis in gliomas. Medical Molecular Morphology 51:4, pages 194-198.
Crossref
Crossref
Jiyoon Seok, Soo‑Hyun Yoon, Sun‑Hee Lee, Jong Hwa Jung & You Mie Lee. (2018) The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway. International Journal of Oncology.
Crossref
Crossref
Mario Luppi, Francesco Fabbiano, Giuseppe Visani, Giovanni Martinelli & Adriano Venditti. (2018) Novel Agents for Acute Myeloid Leukemia. Cancers 10:11, pages 429.
Crossref
Crossref
A.R. Fraser, B. Bacci, M.A. le Chevoir & S.N. Long. (2018) Isocitrate Dehydrogenase 1 Expression in Canine Gliomas. Journal of Comparative Pathology 165, pages 33-39.
Crossref
Crossref
Lucie Petrova, Filip Vrbacky, Miriam Lanska, Alzbeta Zavrelova, Pavel Zak & Katerina Hrochova. (2018) IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?. Clinical Biochemistry 61, pages 34-39.
Crossref
Crossref
Evgenii Shumilov, Johanna Flach, Alexander Kohlmann, Yara Banz, Nicolas Bonadies, Martin Fiedler, Thomas Pabst & Ulrike Bacher. (2018) Current status and trends in the diagnostics of AML and MDS. Blood Reviews 32:6, pages 508-519.
Crossref
Crossref
Silvia Raineri & Jane Mellor. (2018) IDH1: Linking Metabolism and Epigenetics. Frontiers in Genetics 9.
Crossref
Crossref
David Suster, German Pihan, Alexander C. Mackinnon & Saul Suster. (2018) Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma of the Thymus. American Journal of Surgical Pathology 42:9, pages 1224-1236.
Crossref
Crossref
Christophe Willekens, Aline Renneville, Sophie Broutin, Véronique Saada, Jean-Baptiste Micol, Julia Delahousse, Vianney Poinsignon, Claire Bories, Céline Berthon, Raphael Itzykson, Nicolas Boissel, Cyril Quivoron, Marie Terroir-Cassou-Mounat, Jacques Bosq, Claude Preudhomme, Angelo Paci, Virginie Penard-Lacronique & Stéphane De Botton. (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia 32:9, pages 2008-2081.
Crossref
Crossref
Sohita Dhillon. (2018) Ivosidenib: First Global Approval. Drugs 78:14, pages 1509-1516.
Crossref
Crossref
Laura N. Toth, Francine B. de Abreu & Laura J. Tafe. (2018) Non–small cell lung cancers with isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) mutations. Human Pathology 78, pages 138-143.
Crossref
Crossref
Jessica L. Counihan, Elizabeth A. Grossman & Daniel K. Nomura. (2018) Cancer Metabolism: Current Understanding and Therapies. Chemical Reviews 118:14, pages 6893-6923.
Crossref
Crossref
Cesar A. Sommer, Amalia Capilla, Francisco J. Molina-Estevez, Andreia Gianotti-Sommer, Nicholas Skvir, Ignacio Caballero, Sanjib Chowdhury & Gustavo Mostoslavsky. (2018) Modeling APC mutagenesis and familial adenomatous polyposis using human iPS cells. PLOS ONE 13:7, pages e0200657.
Crossref
Crossref
Qian Zhao, James R. Manning, James Sutton, Abran Costales, Martin Sendzik, Cynthia M. Shafer, Julian R. Levell, Gang Liu, Thomas Caferro, Young Shin Cho, Mark Palermo, Gregg Chenail, Julia Dooley, Brian Villalba, Ali Farsidjani, Jinyun Chen, Stephanie Dodd, Ty Gould, Guiqing Liang, Kelly Slocum, Minying Pu, Brant Firestone, Joseph Growney, Tycho Heimbach & Raymond Pagliarini. (2018) Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters 9:7, pages 746-751.
Crossref
Crossref
Michael Buege, Adam DiPippo & Courtney DiNardo. (2018) Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers 10:6, pages 187.
Crossref
Crossref
Alberto Picca, Giulia Berzero, Franck Bielle, Mehdi Touat, Julien Savatovsky, Marc Polivka, Elena Trisolini, Sheida Meunier, Yohann Schmitt, Ahmed Idbaih, Khe Hoang-Xuan, Jean-Yves Delattre, Karima Mokhtari, Anna Luisa Di Stefano & Marc Sanson. (2018)
FGFR1
actionable mutations, molecular specificities, and outcome of adult midline gliomas
. Neurology 90:23, pages e2086-e2094.
Crossref
Crossref
Jungdae Park, Hee-Kyung Na, Hyun Kyong Shon, Hye Young Son, Yong-Min Huh, Sang-Won Lee & Tae Geol Lee. (2018) TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells. Biointerphases 13:3, pages 03B404.
Crossref
Crossref
Fangying Wang, Zhuoling Li, Tao Zhang, Guoyi Yan, Mingxing Hu, Lifeng Zhao, Yinglan Zhao & Yuanwei Chen. (2018) Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chemical Biology & Drug Design 91:6, pages 1087-1093.
Crossref
Crossref
Evgenii Shumilov, Johanna Flach, Thomas Pabst, Martin Fiedler, Anne Angelillo-Scherrer, Lorenz Trümper, Raphael Joncourt, Alexander Kohlmann & Ulrike Bacher. (2018) Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical Reviews in Oncology/Hematology 126, pages 64-79.
Crossref
Crossref
Preethi Kunchala, Sudhakiranmayi Kuravi, Roy Jensen, Joseph McGuirk & Ramesh Balusu. (2018) When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Reviews 32:3, pages 167-183.
Crossref
Crossref
Jiang‐jiang Li, Ruilei Li, Wenxiang Wang, Baihua Zhang, Xin Song, Chunfang Zhang, Yang Gao, Qianjin Liao, Ya He, Shuo You, Zheqiong Tan, Xiangjian Luo, Yueshuo Li, Min Tang, Xinxian Weng, Wei Yi, Shifang Peng, Shaohui Liu, Ying Tan, Ann M. Bode & Ya Cao. (2018)
IDH
2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer
. Molecular Oncology 12:5, pages 602-610.
Crossref
Crossref
Tathiane M Malta, Camila F de Souza, Thais S Sabedot, Tiago C Silva, Maritza S Mosella, Steven N Kalkanis, James Snyder, Ana Valeria B Castro & Houtan Noushmehr. (2018) Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro-Oncology 20:5, pages 608-620.
Crossref
Crossref
Luyan Mu, Yu Long, Changlin Yang, Linchun Jin, Haipeng Tao, Haitao Ge, Yifan E. Chang, Aida Karachi, Paul S. Kubilis, Gabriel De Leon, Jiping Qi, Elias J. Sayour, Duane A. Mitchell, Zhiguo Lin & Jianping Huang. (2018) The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Samantha Moore, Aino I Järvelin, Ilan Davis, Gareth L Bond & Alfredo Castello. (2018) Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer. Current Opinion in Genetics & Development 48, pages 112-120.
Crossref
Crossref
Zhengqiu Zhou, Elochukwu Ibekwe & Yevgen Chornenkyy. (2018) Metabolic Alterations in Cancer Cells and the Emerging Role of Oncometabolites as Drivers of Neoplastic Change. Antioxidants 7:1, pages 16.
Crossref
Crossref
Hye-Young Min & Ho-Young Lee. (2018) Oncogene-Driven Metabolic Alterations in Cancer. Biomolecules & Therapeutics 26:1, pages 45-56.
Crossref
Crossref
Alberto Picca, Giulia Berzero & Marc Sanson. (2018) Current therapeutic approaches to diffuse grade II and III gliomas. Therapeutic Advances in Neurological Disorders 11, pages 175628561775203.
Crossref
Crossref
Peng Gao, Nicole A. Seebacher, Francis Hornicek, Zheng Guo & Zhenfeng Duan. (2018) Advances in sarcoma gene mutations and therapeutic targets. Cancer Treatment Reviews 62, pages 98-109.
Crossref
Crossref
Lucia Salamanca-Cardona, Hardik Shah, Alex J. Poot, Fabian M. Correa, Valentina Di Gialleonardo, Hui Lui, Vesselin Z. Miloushev, Kristin L. Granlund, Sui S. Tee, Justin R. Cross, Craig B. Thompson & Kayvan R. Keshari. (2017) In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. Cell Metabolism 26:6, pages 830-841.e3.
Crossref
Crossref
Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N. Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J. Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson & Meenhard Herlyn. (2017) A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports 21:7, pages 1953-1967.
Crossref
Crossref
Daniel J. Urban, Natalia J. Martinez, Mindy I. Davis, Kyle R. Brimacombe, Dorian M. Cheff, Tobie D. Lee, Mark J. Henderson, Steven A. Titus, Rajan Pragani, Jason M. Rohde, Li Liu, Yuhong Fang, Surendra Karavadhi, Pranav Shah, Olivia W. Lee, Amy Wang, Andrew McIver, Hongchao Zheng, Xiaodong Wang, Xin Xu, Ajit Jadhav, Anton Simeonov, Min Shen, Matthew B. Boxer & Matthew D. Hall. (2017) Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Scientific Reports 7:1.
Crossref
Crossref
Pere Llinàs-Arias & Manel Esteller. (2017) Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biology 7:9, pages 170152.
Crossref
Crossref
Eric Solary & Raphael Itzykson. (2017) How I treat chronic myelomonocytic leukemia. Blood 130:2, pages 126-136.
Crossref
Crossref
M. Touat, A. Idbaih, M. Sanson & K.L. Ligon. (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights. Annals of Oncology 28:7, pages 1457-1472.
Crossref
Crossref
Megan Reed Showalter, Jason Hatakeyama, Tomas Cajka, Kacey VanderVorst, Kermit L CarrawayIIIIII & Oliver Fiehn. (2017) Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. eLife 6.
Crossref
Crossref
Hwajeong Lee & Jeffrey S. Ross. (2017) The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therapeutic Advances in Gastroenterology 10:6, pages 507-520.
Crossref
Crossref
Tom MunyerRobert Mancini. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Parker L. SulkowskiChristopher D. CorsoNathaniel D. RobinsonSusan E. ScanlonKarin R. PurshouseHanwen BaiYanfeng LiuRanjini K. SundaramDenise C. HeganNathan R. FonsGregory A. BreuerYuanbin SongKetu Mishra-GorurHenk M. De FeyterRobin A. de GraafYulia V. SurovtsevaMaureen KachmanStephanie HaleneMurat GünelPeter M. GlazerRanjit S. Bindra. (2017) 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine 9:375.
Crossref
Crossref